Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Rheum Dis ; 21(6): 1277-1286, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29879320

ABSTRACT

PURPOSE: The aim of this study was to determine the effect of active immunization of interleukin (IL)-17A to inhibit B cell functions and monitor the risk of infection in a pristane-induced lupus mice model. METHODS: Female Balb/c mice were given a single intraperitoneal injection of 0.5 mL pristane. IL-17A was coupled to keyhole limpet hemocyanin (KLH) and given to mice in three different doses: D0 (0 µg/mL), D1 (1 µg/mL), and D2 (10 µg/mL). The vaccine was given three times with 3-week intervals. At day 42, mice were injected intraperitoneally with methicillin-resistant Staphylococcus aureus (MRSA) and monitored for 3 weeks. Plasma cells proliferation, Th17 and plasma cell percentages were measured by flow cytometry; anti-IL-17A antibody titers, IL-17A, and anti-double-stranded DNA (anti-dsDNA) levels were measured by enzyme-linked immunosorbent assay; and MRSA colonization was measured by bacterial counter. RESULTS: Anti-IL-17A antibody titers were significantly higher in D2 compared to D0 (P = 0.012). Serum IL-17A levels were also significantly lower in D2 compared to D0 (P = 0.000) while Th17 percentages were not significantly different between groups. D2 was also had significantly lower anti-dsDNA (P = 0.021), lower plasma cell percentages (P = 0.000) and lower B cell proliferation rate (P = 0.001) compared to D0. Analysis for the risk of infection also revealed that D2 did not increase the risk of infection compared to D0 (P = 0.504). CONCLUSION: Active immunization with IL-17A coupled to KLH was able to induce a high titer of neutralizing antibodies against IL-17A and inhibit B cell functions without increasing the risk of infection in a pristane-induced lupus mice model.


Subject(s)
Antibodies, Neutralizing/immunology , B-Lymphocytes/drug effects , Immunization , Interleukin-17/administration & dosage , Lupus Erythematosus, Systemic/drug therapy , Lymphocyte Activation/drug effects , Methicillin-Resistant Staphylococcus aureus/immunology , Staphylococcal Infections/immunology , Terpenes , Adjuvants, Immunologic/administration & dosage , Animals , Antibodies, Antinuclear/blood , Antibodies, Antinuclear/immunology , Antibodies, Neutralizing/blood , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Disease Models, Animal , Female , Hemocyanins/administration & dosage , Hemocyanins/immunology , Immunogenicity, Vaccine , Interleukin-17/blood , Interleukin-17/immunology , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/chemically induced , Lupus Erythematosus, Systemic/immunology , Mice, Inbred BALB C , Staphylococcal Infections/blood , Staphylococcal Infections/diagnosis , Staphylococcal Infections/microbiology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...